Literature DB >> 9605129

Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.

A Rosendahl1, K Kristensson, J Hansson, K Riesbeck, T Kalland, M Dohlsten.   

Abstract

The bacterial superantigen staphylococcal enterotoxin A (SEA) is a potent inducer of cytokine production and cytotoxic T cell responses. To target a T cell attack against tumor cells we have genetically engineered a fusion protein of SEA and the Fab part of the tumor-reactive mAb C215. Injection of this Fab-SEA fusion protein to mice carrying lung metastases of the poorly immunogenic B16 melanoma transfected with the C215 Ag resulted in infiltration of cytokine-producing T cells, perforin-containing CTL, and a marked tumor elimination. Fab-SEA therapy induced substantial levels of IFN-gamma and TNF-alpha in serum. In the present study we have characterized the molecular mechanisms of the antitumor effect induced by Fab-SEA treatment in vivo. Neutralization of cytokines by specific Abs demonstrated a major role for IFN-gamma in the suppression of tumor growth. In addition, a minor contribution of TNF-alpha was recorded. Injections of Fab-SEA into normal mice induced strong CTL activity but failed to promote cytotoxic function in perforin knockout mice. Also, a markedly reduced therapy was noted in perforin knockout mice, implicating a role for CTL in Fab-SEA-mediated tumor eradication. The data suggest that Fab-SEA-targeted T cells may suppress tumor growth by both perforin-dependent cytotoxicity and local release of cytokines such as IFN-gamma. The latter mechanism may have an important role in cytostatic effects against Ag-negative bystander tumor cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605129

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Preparation and activity of conjugate of monoclonal antibody HAb18 against hepatoma F(ab')(2) fragment and staphylococcal enterotoxin A.

Authors:  L J Yang; Y F Sui; Z N Chen
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

Review 2.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  PBMC activation via the ERK and STAT signaling pathways enhances the anti-tumor activity of Staphylococcal enterotoxin A.

Authors:  Xueting Liu; Liping Zeng; Zhongqiu Zhao; Jianxing He; Yang Xie; Lanyan Xiao; Shan Wang; Junyan Zhang; Zehong Zou; Ying He; Ailin Tao; Jianguo Zhang
Journal:  Mol Cell Biochem       Date:  2017-05-03       Impact factor: 3.396

4.  Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells.

Authors:  K Riesbeck; A Billström; J Tordsson; T Brodin; K Kristensson; M Dohlsten
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

5.  A novel approach for cancer immunotherapy: tumor cells with anchored superantigen SEA generate effective antitumor immunity.

Authors:  Wenxue Ma; Hai Yu; Qingqing Wang; Hongchuan Jin; Joyce Solheim; Vinod Labhasetwar
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

6.  Solid tumor-targeted infiltrating cytotoxic T lymphocytes retained by a superantigen fusion protein.

Authors:  Jialin Sun; Lina Zhao; Lijie Teng; Feng Lin; Hongna Zhang; Zhengnan Li; Qiang Gao
Journal:  PLoS One       Date:  2011-02-02       Impact factor: 3.240

7.  The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.

Authors:  M J Litton; M Dohlsten; A Rosendahl; L Ohlsson; M Søgaard; J Andersson; U Andersson
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

8.  Staphylococcal Enterotoxin O Exhibits Cell Cycle Modulating Activity.

Authors:  Elisabeth Hodille; Ludmila Alekseeva; Nadia Berkova; Asma Serrier; Cedric Badiou; Benoit Gilquin; Virginie Brun; François Vandenesch; David S Terman; Gerard Lina
Journal:  Front Microbiol       Date:  2016-04-15       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.